

Supplemental Figures

Figure 1. Histogram shows the distribution of the number of tissues (x-axis) a given enhancer is active in (out of 37 tissues possible).




Figure 2. Fraction of significantly correlated enhancer pairs decreases monotonically with increasing distance between the enhancers, even when *a*) an FDR test conducted on a common pooled background is used. (Bin-wise fractions reflect post-test partitioning of enhancer pairs based on genomic distance), and *b*) a background of trans-chromosomal pairs is used.




Figure 3. Illustrative example of an enhancer cluster. The figure shows on the genome browser a representative cluster of enhancers comprising 117 enhancers spread throughout chromosome 2. This cluster includes 12 strong (blue ticks) and 54 weak enhancers (red ticks) as annotated by ChromHMM. DHS (black ticks) in 5 representative cell types are shown for all enhancers. The figure clearly illustrates the correlated activity of these enhancers across the cell types. This cluster, which was constructed without regard to motif co-occurrence, in fact also broadly shares 2 motifs (magenta ticks).



Supplemental Tables

Supplementary Table 1. 73 cell types were sorted into 37 clusters. One cell type from each cluster (first in row) was used as the representative for the cluster. See text for how the representative was selected.

| Cluster | Cell Types |
|---------|---------------------|
| 1 | A549 |
| 2 | Aoaf M059j |
| 3 | Be2c |
| 4 | Cd20ro01778 |
| 5 | Gm04503 |
| 6 | Gm04504 |
| 7 | Hah |
| 8 | Hasp Nt2d1 |
| 9 | Hbmec Hff |
| 10 | Hipe |
| 11 | Hmf |
| 12 | Hmvecdad |
| 13 | Hmvecdblneo |
| 14 | Hmvecdlyneo |
| 15 | Hmvecclly |
| 16 | Hpaf Hsmtt |
| 17 | Hrgec Th1wb54553204 |
| 18 | Hs5 |
| 19 | Hsmtt |

20 Huvec Hbvp Hct116 Hmec Hmvecdbladd Hmvecdneo Hpdlf Nhek Rpmi7951
Th1 Tregwb83319432 Wi38

21 Jurkat

22 Mcf7 Lhcnm2

23 Monocd14ro1746

24 Msc

25 Nha

26 Nhbera

27 Nhdfad Hmveclbl Hpaec

28 Prec

29 Rptec Gm12864 Hac Hcfaa Hconf Th17

30 Sknmc

31 T47d Cd34mobilized

32 Th1wb33676984

33 Th2

34 Th2wb33676984

35 Th2wb54553204 Cd4naivewb78495824

36 Tregwb78495824 Cd4naivewb11970640 H7es Hbvsmc Hffmyc Hmvecdlyad
Hpf Hs27a Hvmf Lncap

37 Werirb1

Supplementary Table 2. Gene Ontology (GO) annotation terms for the clusters of target genes corresponding to correlated enhancer clustering with the highest ratio of enrichment terms between itself and a background gene cluster. In this list are GO terms separated by targeted gene cluster with adjusted p-values < 0.0005 and that are supported by three or more genes in the cluster. 7 of 52 clusters were enriched for at least one term that met this highly stringent standard. There were 149 separate instances of enrichment. This enhancer cluster was identified using the following parameters: min mean mutual information = 0.2, minimum cluster size = 20, minimum percent occupancy for most enriched motif = 0.0. Background clusters are matched for chromosome, the number of enhancers and signature of inter-enhancer distances, but consist of otherwise random enhancers. GO enrichment analysis performed with R's GOstats package. Adjusted p-value = 0.05*p-value/ q-value.

cluster size: 65 genes

| Enriched term | #genes | Adjusted p-value | Description |
|---------------|--------|------------------|--|
| GO:0009790 | 4 | 3.3e-04 | embryo development |
| GO:0007411 | 3 | 3.3e-04 | axon guidance |
| GO:0051179 | 10 | 3.3e-04 | localization |
| GO:0009605 | 5 | 3.3e-04 | response to external stimulus |
| GO:0051093 | 3 | 3.5e-04 | negative regulation of developmental process |
| GO:0048519 | 8 | 3.5e-04 | negative regulation of biological process |
| GO:0045597 | 3 | 3.5e-04 | positive regulation of cell differentiation |
| GO:0016337 | 3 | 3.5e-04 | cell-cell adhesion |
| GO:0001775 | 4 | 3.5e-04 | cell activation |
| GO:0060284 | 3 | 3.6e-04 | regulation of cell development |

| | | | |
|------------|---|---------|--|
| GO:0051960 | 3 | 4.0e-04 | regulation of nervous system development |
| GO:0048523 | 8 | 4.2e-04 | negative regulation of cellular process |
| GO:0065008 | 8 | 4.2e-04 | regulation of biological quality |
| GO:0072358 | 4 | 4.2e-04 | cardiovascular system development |
| GO:0072359 | 4 | 4.2e-04 | circulatory system development |
| GO:0045596 | 3 | 4.2e-04 | negative regulation of cell differentiation |
| GO:0051129 | 3 | 4.3e-04 | negative regulation of cellular component organization |
| GO:0048568 | 3 | 4.3e-04 | embryonic organ development |
| GO:0071845 | 3 | 4.3e-04 | cellular component disassembly at cellular level |
| GO:0051239 | 6 | 4.3e-04 | regulation of multicellular organismal process |
| GO:0022411 | 3 | 4.3e-04 | cellular component disassembly |
| GO:0050767 | 3 | 4.3e-04 | regulation of neurogenesis |
| GO:0007155 | 5 | 4.3e-04 | cell adhesion |
| GO:0022610 | 5 | 4.3e-04 | biological adhesion |
| GO:0007507 | 3 | 4.3e-04 | heart development |
| GO:0050793 | 5 | 4.3e-04 | regulation of developmental process |
| GO:0030182 | 5 | 4.5e-04 | neuron differentiation |
| GO:2000026 | 5 | 5.0e-04 | regulation of multicellular organismal development |

cluster size: 141 genes

| | | | |
|------------|----|---------|--|
| GO:0048812 | 4 | 2.3e-04 | neuron projection morphogenesis |
| GO:0048667 | 4 | 2.3e-04 | cell morphogenesis involved in neuron differentiation |
| GO:0001525 | 3 | 2.3e-04 | angiogenesis |
| GO:0051172 | 5 | 2.3e-04 | negative regulation of nitrogen compound metabolic process |
| GO:0048585 | 4 | 2.3e-04 | negative regulation of response to stimulus |
| GO:0048568 | 3 | 2.3e-04 | embryonic organ development |
| GO:0007409 | 4 | 2.3e-04 | axonogenesis |
| GO:0001558 | 3 | 2.3e-04 | regulation of cell growth |
| GO:0051090 | 3 | 2.3e-04 | regulation of transcription factor activity |
| GO:0048468 | 6 | 2.3e-04 | cell development |
| GO:0002009 | 3 | 2.3e-04 | morphogenesis of an epithelium |
| GO:0050767 | 3 | 2.3e-04 | regulation of neurogenesis |
| GO:0090046 | 3 | 2.3e-04 | regulation of transcription regulator activity |
| GO:0010629 | 5 | 2.3e-04 | negative regulation of gene expression |
| GO:0007507 | 3 | 2.3e-04 | heart development |
| GO:0007399 | 7 | 2.3e-04 | nervous system development |
| GO:0045934 | 5 | 2.3e-04 | negative regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process |
| GO:0016481 | 5 | 2.4e-04 | negative regulation of transcription |
| GO:0032501 | 16 | 2.5e-04 | multicellular organismal process |
| GO:0001503 | 3 | 2.7e-04 | ossification |
| GO:0035239 | 3 | 2.7e-04 | tube morphogenesis |
| GO:0006357 | 6 | 2.8e-04 | regulation of transcription from RNA polymerase II promoter |

| | | | |
|------------|----|---------|--|
| GO:0042127 | 6 | 2.9e-04 | regulation of cell proliferation |
| GO:0032582 | 3 | 3.0e-04 | negative regulation of gene-specific transcription |
| GO:0008283 | 7 | 3.0e-04 | cell proliferation |
| GO:0050673 | 3 | 3.3e-04 | epithelial cell proliferation |
| GO:0009887 | 5 | 3.3e-04 | organ morphogenesis |
| GO:0042692 | 3 | 3.3e-04 | muscle cell differentiation |
| GO:0007411 | 4 | 3.7e-04 | axon guidance |
| GO:0009890 | 6 | 3.7e-04 | negative regulation of biosynthetic process |
| GO:0002697 | 3 | 3.8e-04 | regulation of immune effector process |
| GO:0048869 | 10 | 3.9e-04 | cellular developmental process |
| GO:0031327 | 6 | 3.9e-04 | negative regulation of cellular biosynthetic process |
| GO:0010553 | 3 | 3.9e-04 | negative regulation of gene-specific transcription from RNA polymerase II promoter |
| GO:0009892 | 7 | 4.1e-04 | negative regulation of metabolic process |
| GO:0031324 | 7 | 4.2e-04 | negative regulation of cellular metabolic process |
| GO:0035295 | 4 | 4.2e-04 | tube development |
| GO:0010605 | 7 | 4.2e-04 | negative regulation of macromolecule metabolic process |
| GO:0045892 | 5 | 4.2e-04 | negative regulation of transcription, DNA-dependent |
| GO:0051253 | 5 | 4.2e-04 | negative regulation of RNA metabolic process |
| GO:0009605 | 7 | 4.2e-04 | response to external stimulus |
| GO:2000113 | 6 | 4.2e-04 | negative regulation of cellular macromolecule biosynthetic process |
| GO:0022603 | 4 | 4.2e-04 | regulation of anatomical structure morphogenesis |
| GO:0060284 | 4 | 4.2e-04 | regulation of cell development |
| GO:0001763 | 3 | 4.2e-04 | morphogenesis of a branching structure |
| GO:0019216 | 3 | 4.2e-04 | regulation of lipid metabolic process |
| GO:0030154 | 10 | 4.2e-04 | cell differentiation |
| GO:0050678 | 3 | 4.2e-04 | regulation of epithelial cell proliferation |
| GO:0031347 | 4 | 4.2e-04 | regulation of defense response |
| GO:0006935 | 5 | 4.2e-04 | chemotaxis |
| GO:0042330 | 5 | 4.2e-04 | taxis |
| GO:0072358 | 5 | 4.2e-04 | cardiovascular system development |
| GO:0072359 | 5 | 4.2e-04 | circulatory system development |
| GO:0061061 | 4 | 4.2e-04 | muscle structure development |
| GO:0010558 | 6 | 4.2e-04 | negative regulation of macromolecule biosynthetic process |
| GO:0061138 | 3 | 4.2e-04 | morphogenesis of a branching epithelium |
| GO:0050727 | 3 | 4.9e-04 | regulation of inflammatory response |
| GO:0051146 | 3 | 4.9e-04 | striated muscle cell differentiation |
| GO:0048754 | 3 | 5.0e-04 | branching morphogenesis of a tube |

cluster size: 33 genes

| | | | |
|------------|---|---|----------------------------|
| GO:0006936 | 3 | 0 | muscle contraction |
| GO:0051259 | 3 | 0 | protein oligomerization |
| GO:0003012 | 3 | 0 | muscle system process |
| GO:0003013 | 3 | 0 | circulatory system process |

| | | | |
|------------|----|---|--|
| GO:0008015 | 3 | 0 | blood circulation |
| GO:0061061 | 3 | 0 | muscle structure development |
| GO:0035556 | 6 | 0 | intracellular signal transduction |
| GO:0022607 | 5 | 0 | cellular component assembly |
| GO:0010627 | 3 | 0 | regulation of intracellular protein kinase cascade |
| GO:0050794 | 13 | 0 | regulation of cellular process |
| GO:0044085 | 5 | 0 | cellular component biogenesis |

cluster size: 6 genes

| | | | |
|------------|---|---|------------------------------------|
| GO:0007268 | 4 | 0 | synaptic transmission |
| GO:0019226 | 4 | 0 | transmission of nerve impulse |
| GO:0035637 | 4 | 0 | multicellular organismal signaling |

cluster size: 27 genes

| | | | |
|------------|----|---|--|
| GO:0001775 | 5 | 0 | cell activation |
| GO:0001568 | 4 | 0 | blood vessel development |
| GO:0001944 | 4 | 0 | vasculature development |
| GO:0051716 | 11 | 0 | cellular response to stimulus |
| GO:0007265 | 3 | 0 | Ras protein signal transduction |
| GO:0007166 | 7 | 0 | cell surface receptor linked signaling pathway |
| GO:0072358 | 4 | 0 | cardiovascular system development |
| GO:0072359 | 4 | 0 | circulatory system development |
| GO:0007165 | 9 | 0 | signal transduction |
| GO:0006928 | 4 | 0 | cellular component movement |
| GO:0007167 | 4 | 0 | enzyme linked receptor protein signaling pathway |
| GO:0023052 | 9 | 0 | signaling |

cluster size: 53 genes

| | | | |
|------------|---|---|--|
| GO:0045785 | 3 | 0 | positive regulation of cell adhesion |
| GO:0007167 | 6 | 0 | enzyme linked receptor protein signaling pathway |
| GO:0071844 | 6 | 0 | cellular component assembly at cellular level |
| GO:0040007 | 5 | 0 | growth |
| GO:0030155 | 3 | 0 | regulation of cell adhesion |
| GO:0032268 | 6 | 0 | regulation of cellular protein metabolic process |
| GO:0051246 | 6 | 0 | regulation of protein metabolic process |
| GO:0048589 | 3 | 0 | developmental growth |
| GO:0031399 | 5 | 0 | regulation of protein modification process |
| GO:0034622 | 4 | 0 | cellular macromolecular complex assembly |
| GO:0071845 | 3 | 0 | cellular component disassembly at cellular level |
| GO:0022411 | 3 | 0 | cellular component disassembly |
| GO:0009967 | 4 | 0 | positive regulation of signal transduction |

| | | | |
|------------|---|---|--|
| GO:0048584 | 5 | 0 | positive regulation of response to stimulus |
| GO:0043623 | 3 | 0 | cellular protein complex assembly |
| GO:0022607 | 6 | 0 | cellular component assembly |
| GO:0010647 | 4 | 0 | positive regulation of cell communication |
| GO:0023056 | 4 | 0 | positive regulation of signaling |
| GO:0031401 | 3 | 0 | positive regulation of protein modification process |
| GO:0007169 | 4 | 0 | transmembrane receptor protein tyrosine kinase signaling pathway |
| GO:0044085 | 6 | 0 | cellular component biogenesis |
| GO:0042060 | 4 | 0 | wound healing |
| GO:0001932 | 4 | 0 | regulation of protein phosphorylation |

clusterID 38 cluster size: 53 genes

| | | | |
|------------|---|---------|--|
| GO:0048583 | 4 | 3.5e-04 | regulation of response to stimulus |
| GO:0007267 | 3 | 3.5e-04 | cell-cell signaling |
| GO:0022008 | 3 | 3.6e-04 | neurogenesis |
| GO:0050793 | 3 | 3.6e-04 | regulation of developmental process |
| GO:0048731 | 5 | 3.7e-04 | system development |
| GO:0048699 | 3 | 3.8e-04 | generation of neurons |
| GO:0030182 | 3 | 4.0e-04 | neuron differentiation |
| GO:0048518 | 5 | 4.0e-04 | positive regulation of biological process |
| GO:0051128 | 3 | 4.0e-04 | regulation of cellular component organization |
| GO:2000026 | 3 | 4.1e-04 | regulation of multicellular organismal development |
| GO:0030030 | 3 | 4.2e-04 | cell projection organization |
| GO:0048522 | 5 | 4.4e-04 | positive regulation of cellular process |
| GO:0045595 | 3 | 4.8e-04 | regulation of cell differentiation |
| GO:0048666 | 3 | 4.9e-04 | neuron development |

Supplementary Table 3. Mapping of tissues between CTen and ENCODE databases. We clustered the 84 tissue types in the CTen database and the 72 types in the ENCODE DHS database into 34 and 23 cytologically motivated classes, respectively. Agreement in tissue enrichment was assessed based on the 17 classes, shown below, that are shared between CTen and ENCODE.

| Encode cell type (enhancer domain) | Tissue class | Cten cell type (gene domain) |
|---------------------------------------|--------------|---------------------------------|
| Cd20ro01778 | blood | 721 b lymphoblasts |
| Cd34mobilized | | bdca4+ dendritic cells |
| Cd4naivewb11970640 | | cd19+ b cells |
| Cd4naivewb78495824 | | cd33+ myeloid |
| Gm12864 | | cd34+ |
| Jurkat | | cd4+ t cells |
| Th1 | | cd56+ nk cells |
| Th17 | | cd71+ early erythroid |

| | | |
|----------------|----------------------|------------------------------------|
| Th1wb33676984 | | cd8+ t cells |
| Th1wb54553204 | | leukemia chronic myelogenous k-562 |
| Th2 | | leukemia lymphoblastic (molt-4) |
| Th2wb33676984 | | leukemia promyelocytic hl-60 |
| Th2wb54553204 | | lymph node |
| Tregwb78495824 | | lymphoma burkitts (daudi) |
| Tregwb83319432 | | lymphoma burkitts (raji) |
| | | whole blood |
| Nhbera | bronchial epithelium | bronchial epithelial cells |
| Hs27a | bone marrow | bone marrow |
| Hs5 | | |
| Be2c | brain | amygdala |
| Hah | | caudate nucleus |
| M059j | | cingulate cortex |
| Nha | | globus pallidus |
| Sknmc | | hypothalamus |
| | | medulla oblongata |
| | | occipital lobe |
| | | olfactory bulb |
| | | parietal lobe |
| | | pineal day |
| | | pineal night |
| | | pituitary |
| | | pons |
| | | prefrontal cortex |
| | | subthalamic nucleus |
| | | temporal lobe |
| | | thalamus |
| | | whole brain |
| Hac | cerebellum | cerebellum |
| | | cerebellum peduncles |
| Hct116 | colon | colorectal adenocarcinoma |
| | | colon |
| Aoaf | endothelium | cd105+ endothelium |
| Hbmec | | |
| Hbvp | | |
| Hbvsmc | | |
| Hmvecdad | | |
| Hmvecdbl | | |
| Hmvecdblneo | | |
| Hmvecdlyad | | |
| Hmvecdlyneo | | |
| Hmvecdneo | | |
| Hmveclbl | | |
| Hmveclly | | |
| Hpaec | | |
| Hpaf | | |
| Huvec | | |
| Hconf | | eye |

| | | |
|----------------|-----------|----------------------------|
| Werirb1 | | retina |
| Hcfaa | heart | atrioventricular node |
| | | cardiac myocytes |
| | | heart |
| Hrgec | kidney | kidney |
| Hpf | lung | fetal lung |
| Nhbera | | lung |
| Wi38 | | |
| Monocd14ro1746 | monocytes | cd14+ monocytes |
| Hsmm | muscle | skeletal muscle |
| Hsmmt | | smooth muscle |
| Lhcnm2 | | |
| Lncap | prostate | prostate |
| Prec | | |
| Gm04503 | skin | skin |
| Gm04504 | | |
| Nhdfad | | |
| Nhek | | |
| Rpmi7951 | | |
| Hasp | spine | dorsal root ganglion |
| | | spine |
| | | superior cervical ganglion |
| | | trigeminal ganglion |
| Nt2d1 | testis | testis |
| | | testis germ cell |
| | | testis interstitial |
| | | testis leydig cell |
| | | testis seminiferous tubule |

Supplementary Table 4. Genes targeted by the enhancer cluster in Figure 6 (see legend in Figure 6 for more information).

- * transport
- * signal transduction
- * nucleocytoplasmic transport
- * embryo development
- * cell death
- * cell differentiation
- * cell signaling
- * anatomical structure formation involved in morphogenesis
- * cell proliferation
- * transmembrane support

| Gene Symbol | Gene Description | GO Slim Terms | | | | | | | | | |
|-------------|------------------------------|---------------|--|---|---|---|--|--|--|---|--|
| STK38L | protein_kinase_activity | * | | | | | | | | | |
| SSPN | cell_junction | | | | | | | | | | |
| DIP2B | transcription_factor_binding | | | | | | | | | | |
| PPM1H | catalytic_activity | | | | | | | | | | |
| KITLG | signal_transduction | * | | * | * | * | | | | * | |

| | | | | | | | | | | |
|----------|---|---|---|---|---|---|---|---|---|---|
| KCNA5 | transmembrane_transport | * | | | | | | * | | * |
| PLEKHA5 | phospholipid_binding | | | | | | | | | |
| WNK1 | protein_kinase_activity | * | * | | | | * | | | |
| ADAMTS20 | proteolysis | | * | | | * | * | | | |
| SRGAP1 | signal_transduction | | * | | | | * | * | | |
| CCDC91 | protein_transport | * | | | | | | | | |
| IFNG | cytokine-mediated_signaling_pathway | * | * | * | | * | * | * | * | * |
| BTBD11 | DNA_binding | | | | | | | | | |
| TMTC2 | endoplasmic_reticulum | | | | | | | | | |
| E2F7 | regulation_of_transcription_DNA-dependent | | * | | * | | * | * | * | * |
| CDK17 | protein_kinase_activity | | | | | | | | | |
| PPTC7 | metal_ion_binding | | | | | | | | | |
| ETNK1 | ATP_binding | | | | | | | | | |
| VEZT | cell_junction | | | | * | | | | | |
| PRICKLE1 | transcription_factor_binding | * | * | * | * | | * | * | | |
| CALCOCO1 | signal_transduction | | * | | | | | | | |
| LIMA1 | cell_junction | | | | | | | | | |
| IFT81 | cell_differentiation | | | | | | * | | | |
| SYT1 | cell_junction | * | | | | | | * | | |
| PTPRQ | receptor_activity | | | | * | | * | * | | |
| CACNA1C | transmembrane_transport | * | | | | | * | * | * | |
| ERC1 | Golgi_membrane | * | * | | | | | | | |
| KRR1 | RNA_binding | | | | | | | | | |
| TMEM117 | integral_to_membrane | | | | | | | | | |
| AEBP2 | regulation_of_transcription_DNA-dependent | | | | | | * | | | |
| DRAM1 | apoptotic_process | | | | | | * | | | |
| NUDT4 | intracellular_signal_transduction | * | * | * | | | | | | |
| EPS8 | signal_transduction | | * | | | | | | * | |
| IFLTD1 | cell_proliferation | | | | | | | | * | |
| ANO6 | ion_transport | * | | | | | | | | * |
| DDX47 | ATP_binding | | | | | * | | | | |
| SLC6A15 | transmembrane_transport | * | | | | | | | | * |
| HPD | Golgi_membrane | | | | | | | | | |
| PTHLH | Golgi_apparatus | | * | | | | * | * | * | * |
| IGF1 | signal_transduction | * | * | * | | * | * | * | * | * |
| STAB2 | receptor_activity | * | | | | | | * | | |
| EEA1 | membrane_fraction | * | | | | | | * | | |
| C1R | proteolysis | * | | | | | | * | | |
| TMEM119 | integral_to_membrane | | | | | | | | | |
| TSPAN11 | membrane | | | | | | | | | |
| PPFIA2 | receptor_activity | | | | | | | | | |
| NCOR2 | negative_regulation_of_transcription_ | | * | | | | | | | |
| ATP2B1 | transmembrane_transport | * | | | | | | | | * |
| MLXIP | regulation_of_transcription_DNA-dependent | * | | * | | | | | | |
| GLIPR1L2 | integral_to_membrane | | | | | | | | | |
| EPYC | extracellular_region | | | | | | | | | |
| PPP1R12A | signal_transducer_activity | * | * | * | | | | | | |
| AMIGO2 | cell_adhesion | | | | | * | | | | |
| FAR2 | endoplasmic_reticulum_membrane | | | | | | | | | |
| BICD1 | transport | * | * | | | | | | | |
| NUAK1 | protein_kinase_activity | | | | | | | | * | |
| SLC38A2 | transmembrane_transport | * | | | | | | * | | * |
| CRADD | signal_transduction | | * | | | * | | | | |
| EP400 | nucleotide_binding | | | | | | | | | |
| DYRK2 | protein_kinase_activity | * | * | * | | * | | | | |
| DCN | extracellular_space | | | | | | | | | |
| ZNF664 | regulation_of_transcription_DNA-dependent | | | | | | | | | |
| SLC41A2 | transmembrane_transport | * | | | | | | | | * |
| HMG2 | negative_regulation_of_transcription_ | * | | | * | * | * | * | * | * |
| PDE3A | signal_transduction | | * | | | * | * | | | |

| | | | | | | | | | |
|----------|--|---|---|---|---|---|---|---|---|
| CHST11 | transferase_activity | * | * | * | * | * | * | * | * |
| PLEKHG6 | phospholipid_binding | * | | | | | | | |
| TMTC3 | integral_to_membrane | | | | | | | | |
| ANO4 | ion_transport | | | | | | | | |
| NAV3 | ATP_binding | | | | | | | | |
| SLC38A4 | transmembrane_transport | * | | | | | | | * |
| ANKS1B | cell_junction | | | | | | | | |
| C12orf70 | integral_to_membrane | | | | | | | | |
| PLCZ1 | intracellular_signal_transduction | * | * | | | | | | |
| HCAR1 | G-protein_coupled_receptor_activity | | | | | | | | |
| CKAP4 | perinuclear_region_of_cytoplasm | | | | | | | | |
| USP15 | proteolysis | | * | | | | | | |
| ITPR2 | transmembrane_transport | * | * | | | * | | | |
| TBX3 | negative_regulation_of_transcription_ | * | | * | * | * | * | * | * |
| PTPRR | receptor_activity | | | * | * | * | | | |
| WNT5B | receptor_binding | | * | * | * | * | * | | |
| TSPAN8 | signal_transducer_activity | | * | | | * | | * | |
| ST8SIA1 | Golgi_membrane | | * | | | | | | * |
| RASSF9 | signal_transduction | * | * | | | | | | |
| TFSM | intracellular | | | | | | | | |
| TEAD4 | regulation_of_transcription_from_RNA_pol_II_promoter | | * | * | * | * | * | | |
| TMEM132B | integral_to_membrane | | | | | | | | |
| PHLDA1 | regulation_of_transcription_from_RNA_polIII_promoter | | | | * | | | | |

Supplemental Notes and Results

1. Incorporating TF gene expression in assessing motif co-occurrence among correlated enhancer pairs.

In result section 5, we sought evidence of co-regulation by comparing the frequency of co-occurrence for each motif in correlated enhancer pairs to its expected frequency. To make these tests more conservative, instances of co-occurrence in a pair were only counted when there was at least one tissue in which both pair members were active and the cognate TF expressed. Motifs were not considered for which binding TF information was not available or that bind to TFs coded for by two or more genes. Approximately one-half (509) of the 981 motifs qualified. TFs were considered expressed in a given tissue if the normalized tag count density exceeded 0, where 0 was chosen due to the lack of any discontinuity in the distribution of tag count densities. (Based on this criterion, on average < 30% of TFs are expressed in each tissue). Under these conditions, there were a total of 67 motifs that co-occurred significantly more often than expected (FDR 5%, based on p-values from Fisher Exact Test) and present in at least 20 pairs, compared to zero motifs that occurred more often than expected in uncorrelated pairs. 20 of the 52 motifs previously found to co-occur out of 981 motifs were among the set of 67, in spite of the reduced test set of motifs. When thresholds of expression higher than 0 were used similar, if fewer, sets of significant motifs resulted (while still no motifs in random pairs

significantly co-occurred).

2. Correlated enhancer clusters share common regulatory motifs

We extended the pair-wise motif co-occurrence analyses to clusters of correlated enhancers. Disjoint clusters with at least 10 enhancers were greedily identified such that mean MI for all pairs within the cluster was at least 0.2 (other thresholds do not change the conclusion). Each TRANSFAC motif was assessed for enrichment in each cluster relative to other clusters based on a Fisher Exact Test, and significance was corrected for multiple testing. At a FDR threshold of 5%, for the 415 clusters, there were 44 instances of cluster-specific enrichments. In contrast, for a background set of 415 clusters using randomly chosen enhancers (mean pairwise I within a cluster $\ll 0.1$) sampled to match total motif occupancy, mean GC content, and the cluster size of the foreground, there were only 2 instances of cluster-specific enrichment.

3. Correlated enhancer pairs are potentially co-regulated

Co-regulated enhancers tend to share common motifs {Berman, 2004 #7}. To investigate whether the enhancer pairs with correlated activity are potentially co-regulated, next we tested whether correlated enhancers share significantly greater numbers of motifs than expected. We quantified motif overlap between the two enhancers using Jaccard index, defined as the ratio of the sizes of the intersection and the union of the two motifs sets. Separately for each distance-bin we compared Jaccard index values for the highly correlated enhancer pairs with those for pairs in the background using a Wilcoxon rank-sum test. The foreground and the background enhancer pairs were selected as for Result section 5 above. We found that in every distance bin the foreground pairs have a significantly greater fraction of shared motifs, with p-values ranging from $1.6e-04$ to $6.1e-33$ (Table 3a). The result remains highly significant when we repeated the analysis at the level of motif clusters instead of individual motifs (see M&M). As expected, the difference between foreground and background is amplified when only 52 significantly co-occurring motifs (section 5) were used to calculate Jaccard index (Table 3b). These results suggest that enhancer pairs highly correlated in their chromatin state share multiple motifs and are likely to be co-regulated.

4. Presence of shared motifs is predictive of enhancer DHS correlation

We assessed, using machine learning, whether the presence of common motifs can predict correlated activity of a pair of enhancers. For each enhancer pair we assigned one attribute per motif. The value of

the attribute was set to 1 if both enhancers had a motif instance and 0 otherwise. We then trained and tested a support vector machine (SVM) to discriminate between the foreground (FDR 0.01% was used for computational tractability) and the background enhancer pairs, using 10-fold cross validation. When using all 981 motifs as attributes, the SVM achieved an overall average classification accuracy of 73%. Importantly, there was very little reduction in performance (70%) when the model used only the 52 significantly co-occurring motifs (section 5). However, when we used 52 random motifs, the SVM accuracy was reduced to 55%, not much greater than random expectation of 50%. This result suggests that shared occurrence of a specific set of motifs is predictive of correlated enhancer activity.

5. Interactions between enhancer motifs and chromatin modification enzymes

To further probe the potential involvement of chromatin modification enzymes (CME) in regulating correlated enhancer activities, we assessed CMEs for their preferential interactions with the 52 motifs (Table 1) that significantly co-occur in correlated enhancers. The 52 motifs mapped to 146 unique proteins using TRANSFAC and ENSEMBL databases, while the remaining motifs mapped to 2227 proteins. There are more proteins than motifs due to ambiguous mapping of motifs to isoforms. A list of 828 CMEs was extracted from ENSEMBL database (version 67) based on GO term 'chromatin modification'. Protein-protein interactions were obtained from STRING database using the 'experimental' track. We assessed each of the 828 CMEs for preferential interaction with 146 TFs corresponding to significant motifs relative to the other 2227 TFs, using a Fisher Exact test, followed by multiple testing correction. At FDR = 5% we detected 28 CMEs to preferentially interact with significant TFs (Table 2). In contrast, there was no CME that preferentially interacted with non-significant TF. This result is especially interesting given that overall, the 146 significant TFs do not interact with CMEs any more than the other 2227 TFs.

6. Targets of correlated enhancer clusters have correlated expression and shared function

Next we extended our analyses in section 9 to clusters of correlated enhancers. We identified clusters of five or more enhancers that were mutually correlated (various thresholds from 0.2 to 0.5 were used), while enriched for at least one of the previously identified significantly enriched motif cluster. For each enhancer cluster a control cluster was created from non-correlated enhancers that mirrored the former's size and genomic footprint (i.e. intra-cluster genomic distances). As was true for correlated enhancer pairs, putative targets of correlated clusters (*i.e.*, the set of genes nearest to each enhancer), were more highly correlated in their normalized RNA-seq transcript counts than were background clusters. For each triplet of thresholds for (i) minimum cluster size (5-20), (ii) minimum pairwise I (0.2-0.5) within a cluster, and (iii) minimum fraction of cluster members (0.7-0.8) harboring the most

enriched meta-motif, the genes targeted by enhancers in clusters had higher Spearman correlation of transcription levels than the matching set of background enhancer clusters. For each parameter triplet, we compared the foreground and background for mean pair-wise correlation of expression within clusters. For the entire range of parameters, mean expression correlation within foreground clusters was consistently greater than for corresponding expression correlations within background clusters. Due to the variability in cluster counts for different parameters, p-values ranged from 0.02 to 4.1×10^{-15} (Wilcoxon rank-sum test). These results suggest that gene targets of correlated enhancer clusters with shared motifs are co-expressed and presumably co-regulated.

Next we assessed enrichment of GO biological processes amongst the targets of an enhancer cluster using R's GOstats package. Enhancer clusters also revealed consistently greater GO functional enrichment than the background clusters. Across 10 parameter settings, the ratio of enriched GO terms (at FDR 0.01) per foreground cluster to enriched GO terms per background cluster ranges from 1.3-fold to 4.8-fold. On average, there is almost 3-fold higher GO term enrichment in the foreground (19.1 terms per cluster). When the FDR threshold is set to ~ 0 (i.e., $p < 1 \times 10^{-8}$), there is 5-fold higher enrichment, on average, in the foreground (7.5 terms per cluster). As an example, for the parameter setting with the greatest fold enrichment of GO terms, the enriched terms are shown, separated by cluster, in Supplementary Table 3. These terms are consistently revealed across all parameter settings. Together, the GO enrichment and gene expression results illustrate that co-expression of genes with shared function is coordinately regulated across tissues by enhancers that share motifs and are epigenetically correlated across the same tissues.